GenoFAB is a highly specialized platform dedicated to the field of synthetic biology that provides end-to-end and integrated plasmid management services expressly designed to meet the particular needs of research institutions, drug discovery teams, and biomanufacturing organizations. The essential aspect of what GenoFAB provides is its excellent capacity to efficiently streamline the entire lifecycle of plasmids, encompassing all phases from the initial design and synthesis stages through sequencing, biobanking, and secure distribution. Users can access individual services, such as plasmid design using advanced CAD software and curated genetic libraries, or opt for comprehensive management that covers every phase of plasmid handling. GenoFAB’s transparent pricing model, with clearly listed costs for design, synthesis, sequencing, and repository services, ensures predictability and eliminates hidden expenses, making it easier for organizations to plan and scale their projects without budget overruns. By effectively addressing and managing the inherent intricacies in handling plasmids, GenoFAB enables scientists to direct their time and resources towards high-value activities such as discovery, hypothesis testing, and diligent data accumulation. Such a shift liberates them to invest their time and effort in these valuable scientific endeavors, rather than being mired in the technical complexities and logistical challenges inherent in construction management and cloning. One of the features of GenoFAB is that it integrates state-of-the-art technology and automation to provide maximum efficiency, traceability, and security. The platform utilizes a state-of-the-art and proprietary laboratory information management system, commonly referred to as LIMS, that exploits the capabilities of barcoding alongside advanced inventory management techniques. The novel system is custom-designed to monitor plasmids exhaustively at every step of the process, thereby guaranteeing very high degrees of accurate monitoring without simultaneously heightening the risk of sample misidentification or possible loss. GenoFAB's neatly ordered assembly processes are, furthermore, expertly crafted to maximize the recycling of pre-existing genetic material wherever possible. The meticulous approach translates into a remarkable reduction in the need for expensive de novo synthesis, without sacrificing the capacity to produce plasmids quickly and to specification. Furthermore, GenoFAB has taken a revolutionary step in the field by pioneering the new application of DNA cryptography and digital certificates. They have achieved this incredible feat by embedding cryptographic signatures directly into the sequences of plasmids. This breakthrough innovation provides users with the capability to verify the integrity and authenticity of plasmids efficiently and effectively without having to access sensitive and potentially confidential documents. As a result, this innovation significantly enhances intellectual property protection and fosters a greater sense of trust in collaborative research environments. The company developed and patented a breakthrough technology known as the Genetic Sequence Identifier Number, or GSIN. The breakthrough technology enables the manufacturing of self-documenting plasmids, which greatly simplifies sequence verification. Further, it is instrumental in enabling both clinical and commercial applications of these sequences to achieve regulatory compliance requirements. GenoFAB's technologies are optimized to enable a wide range of scientific and industrial applications. Researchers in academia enjoy robust plasmid management that streamlines publication and minimizes experimental risk, while drug discovery teams utilize GenoFAB's high-volume services to iterate and prototype genetic constructs in minutes. For biomanufacturing, GenoFAB helps to optimize expression vectors and build robust, dependable supply chains for plasmids that are essential to the production of therapeutics, vaccines, and other biotechnology products. Platform automation is not confined to lab activities alone but includes computational workflow and interaction with outside collaborators, with uninterrupted data flow and actionable intelligence for all stakeholders. Underpinned by NIH and NSF funding, and by an emphasis on reproducibility and scalability, GenoFAB positions itself as a collaborative partner in scientific innovation, enabling organizations to confidently and effectively bring game-changing genetic products to market.
GenoFAB is the market leader by a wide margin, clearly setting itself apart from the competition by providing an extremely integrated and innovative solution that is fundamentally technology-driven when it comes to plasmid management. This novel strategy effectively solves and addresses the most important issues and complexities that are generally encountered by academic researchers, biotechnology firms, and biomanufacturers alike. In stark contrast with conventional laboratory information management systems (LIMS) or off-the-shelf inventory management solutions, which might provide limited functionality, GenoFAB has been specifically designed with the express intention to cover the entire life cycle of plasmids. This includes all critical phases, from the very first design and synthesis steps through sequencing, biobanking, and ultimately, secure distribution. This comprehensive end-to-end model means that customers can trust one reliable partner to provide all their plasmid requirements. This essentially removes the lack of efficiency and risk that typically comes with broken workflows or having multiple vendors as part of the process. GenoFAB's application of cutting-edge CAD software and hand-crafted genetic libraries facilitates fast, tailored plasmid design, while its assembly procedures ensure maximum reuse of pre-existing genetic material, saving cost and turnaround time over competitors who tend to rely on less flexible, slower techniques. One of the most significant factors that sets GenoFAB apart from the rest is its unwavering commitment to transparency, predictability, and maintaining high quality at each stage of the process. The company has transparent and easily understandable pricing structures for every single service, such as service design, synthesis, sequencing, and repository management. Such transparency allows customers to steer clear of any hidden costs and surprise budget overruns that are otherwise very common with most other vendors in the marketplace. Furthermore, GenoFAB is firmly committed to delivering predictable timelines for every project. Through their extremely streamlined processes and a team of fully dedicated professionals, they keep every project on track and on its planned timeline, even going so far as to work on weekends when required to fulfill urgent deadlines. This reliability is especially valuable both in the research and product development fields since even slight delays in plasmid delivery can cause substantial stalling of whole projects, sending timelines and goals off track. Besides this, GenoFAB uses a rigorous and exhaustive quality control process combined with data-driven design strategies that all work together to ensure only the best quality plasmids are delivered to clients. This, in turn, aids in achieving solid scientific outcomes as well as reproducibility, a factor in which most of the competition sadly comes up short in their services. Security, traceability, and regulatory readiness are additional domains in which GenoFAB is superior. The platform uses the most advanced inventory management systems, state-of-the-art barcoding technologies, and high-end DNA cryptography techniques to track plasmids with high efficiency and securely process plasmids through every stage in their lifecycle. This safeguards valuable intellectual property while simultaneously improving and simplifying collaborations. These types of features matter especially to institutions and biomanufacturers who are moving to clinical or commercial phases. The reason is that processes at GenoFAB, having been thoughtfully designed, maintain a keen consideration of regulatory compliance and so make the process much easier to go through from the early research stages to market readiness. By consolidating strategically a wide array of capabilities into a single scalable and integrated solution, GenoFAB allows scientists and organizations alike to concentrate on their areas of core competency, whether that is in the discovery spaces, innovation development, or the optimization of the manufacturing processes. This allows them to direct their energies and resources into doing what they do best, meanwhile eliminating dramatically administrative hassles that tend to slow things down. This approach also works to significantly minimize the associated risks and decrease the valuable time it takes to bring products to market. This comprehensive and well-managed approach is precisely what distinguishes GenoFAB as an industry superior choice compared to other, more generalist competitors in the field of plasmid management, who do not necessarily have access to the same level of specialization and focused expertise.
Seller
GenoFAB, Inc
HQ Location
Fort Collins, Colorado, USA
Company Website
https://genofab.com/
Contact
+1 9708172400
Year Founded
2019
Plasmid design with CAD software
Genetic component libraries
Plasmid synthesis services
Whole plasmid sequencing
Plasmid repository/biobanking
Web-based barcode and label printing
Sample tracking and management
Inventory management
Request a price
Get the most out of reviews;
leverage the power of AI to achieve success!
How is GenoFAB in terms of value for money?
for my 10000 people companyHow is GenoFAB in terms of ease of use?
for my 10000 people companyEnglish
Where does GenoFAB have offices in GCC?
Not available.
Who are GenoFAB customers in the Middle East?
Not available.
What is GenoFAB local address?
Not available.
Is GenoFAB Platform available in Arabic?
Not available.
Does GenoFAB platform use AI? And where?
GenoFAB leverages artificial intelligence (AI) and machine learning in specific areas of its platform and services, particularly in plasmid sequencing and bioinformatics.
Plasmid Sequencing Service: GenoFAB hybrid plasmid sequencing service, launched in 2025, incorporates machine learning and AI to enhance the accuracy and reproducibility of sequencing workflows. The service uses a new bioinformatics pipeline-developed and published by the GenoFAB team-that applies AI to ensure the integrity and reliability of plasmid sequence data. This is especially important for identifying errors, managing complex sequences, and maintaining quality control throughout the plasmid lifecycle.
Bioinformatics Pipelines: The AI-driven bioinformatics tools are integral to GenoFAB’s approach for validating and managing plasmid integrity. By combining data from long-read (Oxford Nanopore) and short-read (Illumina) sequencing platforms, the AI algorithms help resolve structural variants and improve base-level accuracy, addressing challenges that traditional sequencing methods face.
Is GenoFAB a Web3 company?
No.
Are there any Web3 components in GenoFAB?
No.
GenoFAB
By GenoFAB, Inc
